← back to search

Lingxiao Li

Shenyang Pharmaceutical University · CN
Area of research
Metals and Alloys · Materials Chemistry
Research interest
Research interests include Hydrogen embrittlement and corrosion behaviors in metals, Nanoparticle-Based Drug Delivery, Corrosion Behavior and Inhibition, and Lymphoma Diagnosis and Treatment.
h-index
20
citations
1,801
works
121
NIH funding
primary concept
email

Recent publications

Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax
Blood Cancer Journal 2025cited by 9position: middledoi
Optimizing structural design in SN38 delivery: More assembly stability and activation efficiency
Nano Today 2024cited by 8position: middledoi
Effects of Sc Addition and Retrogression and Re-aging on Microstructure and Mechanical Properties of Al-8Zn-2Mg-2Cu-0.15Zr Alloy
Journal of Materials Engineering and Performance 2022cited by 9position: lastdoi
Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors
Cancer Research 2021cited by 25position: middledoi
Hot Processing Map of an Al–4.30 Mg Alloy under High One-Pass Deformation
Metals 2021cited by 8position: lastdoi
The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma
Oncogene 2019cited by 14position: middledoi
Statins enhance efficacy of venetoclax in blood cancers
Science Translational Medicine 2018cited by 86position: middledoi
Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with <i>In Vivo</i> Antitumor Activity
Clinical Cancer Research 2018cited by 45position: middledoi
Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer
International Journal of Molecular Sciences 2017cited by 438position: middledoi
Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies
Blood 2017cited by 167position: middledoi
Preparation and properties of lambda-cyhalothrin/polyurethane drug-loaded nanoemulsions
RSC Advances 2017cited by 56position: middledoi
Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447
Oncotarget 2016cited by 23position: middledoi
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors
Oncotarget 2016cited by 22position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jonathan H. Schatz · University of Miami7 papers (2016–2025)Amit Dipak Amin · University of Cambridge4 papers (2016–2019)Daniel Bilbao · University of Miami3 papers (2019–2025)Praechompoo Pongtornpipat · University of Arizona3 papers (2016–2018)Zhiliu Hu · Guangxi University2 papers (2021–2022)Francisco Vega · The University of Texas MD Anderson Cancer Center2 papers (2018–2021)Evan R. Roberts · University of Miami2 papers (2019–2021)Yanjun Zhao · Anhui Medical University2 papers (2021–2022)Tara L. Peters · Nivalis Therapeutics (United States)2 papers (2016–2018)Artavazd Arumov · University of Miami2 papers (2019–2021)Jingrui Zhang · Guangxi University2 papers (2021–2022)Soumya Sundara Rajan · Center for Cancer Research2 papers (2016–2019)Feng‐Chun Yang · The University of Texas at San Antonio Health Science Center1 papers (2017–2017)He Qin · Ministry of Education of the People's Republic of China1 papers (2017–2017)Erwei Zhao · Shenyang Pharmaceutical University1 papers (2024–2024)Fen Pei · University of Arizona1 papers (2017–2017)Luis A. Amador · Scripps Institution of Oceanography1 papers (2018–2018)Guangbo Liu · Inner Mongolia University1 papers (2017–2017)Aimin Yan · Shanghai Normal University1 papers (2019–2019)Catalina Amador · University of Miami1 papers (2025–2025)